|
Press Release |
4 July 2008 |
LiDCO Group Plc
("LiDCO" or the "Company")
TR-1: Notification of Major Interests in Shares
LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, today gives notification of major interests in shares.
|
1. |
Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: LIDCO GROUP PLC |
|||||
|
2. |
Reason for the notification An acquisition or disposal of voting rights: Yes |
|||||
|
3. |
Full name of person(s) subject to the notification obligation: AXA S.A. |
|||||
|
4. |
Full name of the shareholder(s) (if different from 3): N/A |
|||||
|
5. |
Date of transaction and date on which the threshold is crossed or reached: 2 July 2008 |
|||||
|
6. |
Date on which issuer notified: 3 July 2008 |
|||||
|
7. |
Threshold(s) that is/are crossed or reached: 5% |
|||||
|
8. |
Notified details: |
|||||
|
A: Voting rights attached to shares |
||||||
|
|
Situation previous to the triggering transaction |
|||||
|
Class of shares |
Number of Shares |
Number of Voting Rights |
||||
|
Ordinary Shares GB0030546849 |
8,852,942 |
8,852,942 |
||||
|
|
Resulting situation after the triggering transaction |
|||||
|
Class of shares |
Number of Shares |
Number of Voting Rights |
% of Voting Rights |
|||
|
|
Direct |
Direct |
Indirect |
Direct |
Indirect |
|
|
Ordinary Shares GB0030546849 |
0 |
0 |
5,801,470 |
0 |
4.09 |
|
|
B: Financial Instruments |
|||
|
Resulting situation after the triggering transaction |
|||
|
Type of Financial Instrument |
Expiration date |
Exercise/Conversion Period/Date |
Number of Voting Rights that may be acquired if the instrument is exercised/converted |
|
N/A |
N/A |
N/A |
N/A |
|
Total (A + B) |
|
||
|
Number of Voting Rights |
% of Voting Rights |
||
|
5,801,470 |
4.09% |
||
|
9. |
Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable: AXA Framlington Indirect 5,801,470 4.08603% |
|
10. |
Name of the proxy holder: N/A |
|
11. |
Number of voting rights proxy holder will cease to hold: N/A |
|
12. |
Date on which proxy holder will cease to hold voting rights: N/A |
|
13. |
Additional information: N/A |
|
14. |
Contact name: Terry Marsh |
|
15 |
Contact telephone number: 020 7003 2637 |
- ENDS -
For more information please contact:
|
LiDCO Group Plc |
|
|
Terry O'Brien - Chief Executive John Rowland - Company Secretary |
Tel: +44 (0)20 7749 1500 |
|
|
|
Panmure Gordon and Co |
|
|
Edward Farmer/ Katherine Roe |
+44 (0)20 7459 3600 |
|
|
Media enquiries
|
Abchurch Communications |
|
|
Heather Salmond / Stephanie Cuthbert / Simone Alves |
+44 (0)20 7398 7728 |
About LiDCO Group Plc
LiDCO is a leading supplier of minimally invasive hemodynamic monitoring equipment and disposables. These are used primarily for the management of hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology significantly reduces the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.
The Company's manufacturing facility is in Hoxton, London and its current products are:
* LiDCOplus and PulseCO monitors: these computer-based platforms are used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid volume (PPV% and SVV%)
* LiDCO disposables: used in conjunction with the LiDCOplus Monitor for accurate measurement of cardiac output in a minimally invasive manner
* LiDCOview: an easy-to-use graphical display of historical LiDCOplus hemodynamic data. Both clinical researchers and routine users can view beat-to-beat hemodynamic data collected with the LiDCOplus. LiDCOviewSE is the standard version of this tool and is available for free, allowing anyone to download and access data from the LiDCOplus. LiDCOviewPRO is the Professional version, allowing users to analyse, export and report the LiDCOplus data. A free trial of LiDCOviewPRO is available for evaluation purposes prior to purchase
* LiDCOlive: a software product in development for the remote display of hemodynamic monitoring parameters derived through use of the LiDCOplus or LiDCOrapid monitors
* LiDCOrapid : our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management at the point of care
Distribution Network:
The Company has now achieved registration of its products in 14 markets in Europe, the USA, Brazil, South Korea and Japan. It sells direct in the UK and USA, and elsewhere through a worldwide network of speciality critical care and anesthesia distributors.